Journal Article

A Trem2 R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques

Gantuz, Magdalena, Kramár, Enikö A, Milinkeviciute, Giedre, Tenner, Andrea J, Kawauchi, Shimako, Walker, Amber, Forner, Stefania, Shi, Kai-Xuan, Rezaie, Narges, Wang, Shuling, Sakr, Jasmine S, Javonillo, Dominic I, Collins, Sherilyn, Shi, Zechuan, Neumann, Jonathan, Liang, Heidi Yahan, Arreola, Miguel A, Phan, Jimmy, Filimban, Ghassan, Wood, Marcelo A, Tran, Kristine M, Green, Kim N, Swarup, Vivek, Gomez-Arboledas, Angela, Tran, Katelynn, LaFerla, Frank M, Cunha, Celia da, Mortazavi, Ali, MacGregor, Grant R

2023

Overview

The TREM2 R47H variant is one of the strongest genetic risk factors for late-onset Alzheimer's Disease (AD). Unfortunately, many current Trem2 mouse models are associated with cryptic mRNA splicing of the mutant allele that produces a confounding reduction in protein product. To overcome this issue, we developed the Trem2 (Normal Splice Site) mouse model in which the Trem2 allele is expressed at a similar level to the wild-type Trem2 allele without evidence of cryptic splicing products. Trem2 mice were treated with the demyelinating agent cuprizone, or crossed with the 5xFAD mouse model of amyloidosis, to explore the impact of the TREM2 R47H variant on inflammatory responses to demyelination, plaque development, and the brain's response to plaques. Trem2 mice display an appropriate inflammatory response to cuprizone challenge, and do not recapitulate the null allele in terms of impeded inflammatory responses to demyelination. Utilizing the 5xFAD mouse model, we report age- and disease-dependent changes in Trem2 mice in response to development of AD-like pathology. At an early (4-month-old) disease stage, hemizygous 5xFAD/homozygous Trem2 (5xFAD/Trem2 ) mice have reduced size and number of microglia that display impaired interaction with plaques compared to microglia in age-matched 5xFAD hemizygous controls. This is associated with a suppressed inflammatory response but increased dystrophic neurites and axonal damage as measured by plasma neurofilament light chain (NfL) level. Homozygosity for Trem2 suppressed LTP deficits and loss of presynaptic puncta caused by the 5xFAD transgene array in 4-month-old mice. At a more advanced (12-month-old) disease stage 5xFAD/Trem2 mice no longer display impaired plaque-microglia interaction or suppressed inflammatory gene expression, although NfL levels remain elevated, and a unique interferon-related gene expression signature is seen. Twelve-month old Trem2 mice also display LTP deficits and postsynaptic loss. The Trem2 mouse is a valuable model that can be used to investigate age-dependent effects of the AD-risk R47H mutation on TREM2 and microglial function including its effects on plaque development, microglial-plaque interaction, production of a unique interferon signature and associated tissue damage.

• Publisher: BMC
• Subject: Alzheimer Disease - metabolism / Alzheimer’s Disease / Animals / Brain - metabolism / Cuprizone - metabolism / Demyelinating Diseases - metabolism / Demyelinating Diseases - pathology / Disease Models, Animal / Inflammation / LTP / Membrane Glycoproteins - genetics / Membrane Glycoproteins - metabolism / Mice / Microglia / Microglia - metabolism / MODEL-AD / Mutation / Plaque, Amyloid - pathology / Receptors, Immunologic - genetics / Receptors, Immunologic - metabolism / RNA Splicing / TREM2 R47H